Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion

Planta Medica

Volumn 72, Issue 14, 2006, Pages 1311-1317

  Hao, Haiping ^a   Wang, Guangji ^a   Cui, Nan ^a   Li, Jing ^a   Xie, Lin ^a   Ding, Zuoqi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Absorption; Pharmacokinetics; Protein binding; Tanshinone IIA; Tissue distribution

Indexed keywords

DIAZEPAM; TANSHINON IIA; TANSHINONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ISOLATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG TRANSPORT; LIQUID CHROMATOGRAPHY; LIVER; LUNG; NONHUMAN; PLASMA PROTEIN BINDING; RAT; RETICULOENDOTHELIAL SYSTEM; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DRUGS, CHINESE HERBAL; HUMANS; INFUSIONS, INTRAVENOUS; LIVER; LUNG; PHENANTHRENES; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; TISSUE DISTRIBUTION;

SALVIA MILTIORRHIZA;

EID: 33845254587     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-951698     Document Type: Article

References (21)

1. Cao EH, Liu XQ, Wang JJ, Xu NF. Effect of natural antioxidant tanshinone II-A on DNA damage by lipid peroxidation in liver cells. Free Radic Biol Med 1996; 20: 801-6
2. Li XH, Tang RY. [Relationship between inhibitory action of tanshinone on neutrophil function and its prophylactic effects on myocardial infarction]. Zhongguo Yao Li Xue Bao 1991; 12: 269-72
3. Yuan SL, Wang XJ, Wei YQ. [Anticancer effect of tanshinone and its mechanisms]. Ai Zheng 2003; 22: 1363-6
4. Wang X, Wei Y, Yuan S, Liu G, Lu Y, Zhang J et al. Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 2005; 116: 799-807
5. Wang X, Yuan S, Wang C. [A preliminary study of the anti-cancer effect of tanshinone on hepatic carcinoma and its mechanism of action in mice]. Zhonghua Zhong Liu Za Zhi 1996; 18: 412-4
6. Kim HH, Kim JH, Kwak HB, Huang H, Han SH, Han H et al. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge. Biochem Pharmacol 2004; 67: 1647-56
7. Lam BY, Lo AC, Sun X, Luo HW, Chung SK, Sucher NJ. Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice. Phytomedicine 2003; 10: 286-91
8. Xia WJ, Yang M, Fok TF, Li K, Chan WY, Ng PC et al. Partial neuroprotective effect of pretreatment with tanshinone IIA on neonatal hypoxia-ischemia brain damage. Pediatr Res 2005; 58: 784-90
9. Hao H, Wang G, Li P, Li J, Ding Z. Simultaneous quantification of cryptotanshinone and its active metabolite tanshinone IIA in plasma by liquid chromatography/tandem mass spectrometry (LC-MS/MS). J Pharm Biomed Anal 2006; 40: 382-8
10. Chen F, Luo HW. Observation on the hydrophobic interaction of tanshinone IIA by transmission electron microscope. J Chin Electr Microscop Soc 2003; 22: 16-20
11. Ezeh B, Haiman M, Alber HF, Kunz B, Paulweber B, Lingenhel A et al. Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls. J Lipid Res 2003; 44: 1523-9
12. Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002; 24: 2022-50
13. Bravo Gonzalez RC, Huwyler J, Walter I, Mountfield R, Bittner B. Improved oral bioavailability of cyclosporin A in male Wistar rats. Comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int J Pharm 2002; 245: 143-51
14. Kuchimanchi KR, Udata C, Johnston TP, Mitra AK. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats. Drug Metab Dispos 2000; 28: 403-8
15. Rivory LP, Pond SM, Winzor DJ. The influence of pH on the interaction of lipophilic anthracyclines with bovine serum albumin. Quantitative characterization by measurement of fluorescence quenching. Biochem Pharmacol 1992; 44: 2347-55
16. Demant EJ, Jensen PB, Sehested M. Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins. Biochim Biophys Acta 1991; 1118: 83-90
17. Li P, Wang GJ, Li J, Hao HP, Zheng CN. Characterization of metabolites of tanshinone IIA in rats by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2006; 41: 670-84
18. Wasan KM, Ramaswamy M, McIntosh MP, Porter CJ, Charman WN. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normolipidemic and dyslipidemic human plasmas. J Pharm Sci 1999; 88: 185-90
19. Hughes TA, Gaber AO, Montgomery CE. Plasma distribution of cyclosporine within lipoproteins and "in vitro" transfer between very-low-density lipoproteins, low-density lipoproteins, and high-density lipoproteins. Ther Drug Monit 1991; 13: 289-95
20. Wasan KM, Kennedy AL, Cassidy SM, Ramaswamy M, Holtorf L, Chou JW et al. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob Agents Chemother 1998; 42: 3146-52
21. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-20